Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Moodys
Dow

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARESTIN

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Arestin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00371332 Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis Completed OraPharma Phase 3 2004-01-01 The purpose of this study is to measure the antimicrobial effects of Arestin in subjects with moderate to advanced periodontal disease
NCT01517334 Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation) Completed OraPharma Phase 3 2012-05-01 The objective of the study is to evaluate the safety, effectiveness and anti-microbial effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites.
NCT01531582 Minocycline in the Treatment of Angelman Syndrome Unknown status University of South Florida N/A 2012-04-01 There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics. However, a recent surge of potential therapeutics for other disorders associated with cognitive disruption has begun to be used in human clinical trials. The molecular modes of action for many of these new therapeutic agents have correlates to counter the molecular defects observed in AS. One such agent is minocycline (MC), a drug traditionally used as an antibiotic. This compound administered to a mouse model of AS showed a significant decrease in motor deficit and an increase in long term potentiation. The investigators believe a similar result will be observed when minocycline is administered to the AS patient and may lead to the development of an effective AS therapeutic.
NCT01539564 Arestin - Use in Subjects With Peri-Implantitis Completed OraPharma Phase 3 2012-04-01 The objective of the study is to evaluate the safety and effectiveness of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Arestin

Condition Name

Condition Name for Arestin
Intervention Trials
Peri-Implantitis 2
Minocycline HCl Microspheres 1
Chronic Kidney Disease 1
Biomarkers 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Arestin
Intervention Trials
Peri-Implantitis 2
Kidney Diseases 1
Gingival Diseases 1
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Arestin

Trials by Country

Trials by Country for Arestin
Location Trials
United States 25
Sweden 1
Germany 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Arestin
Location Trials
Maryland 3
Virginia 2
North Carolina 2
Tennessee 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Arestin

Clinical Trial Phase

Clinical Trial Phase for Arestin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Arestin
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 1
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Arestin

Sponsor Name

Sponsor Name for Arestin
Sponsor Trials
OraPharma 3
University of Minnesota - Clinical and Translational Science Institute 1
Bausch Health Companies, INC. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Arestin
Sponsor Trials
Other 4
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
Moodys
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.